Education
About Us
Working with TipRanks
Follow Us
Zevra Therapeutics (ZVRA)
NASDAQ:ZVRA
ZVRA Analyst Ratings
Strong Buy
7 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ZVRA Stock 12 Month Forecast
Average Price Target
$24.17
▲(99.26% Upside)
| Highest Price Target$29.00 | Average Price Target$24.17 | Lowest Price Target$19.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$12
Hold
-1.07%
Downside
Reiterated
07/26/25
Zevra Therapeutics' overall stock score reflects significant financial challenges, primarily negative profitability and cash flow issues. However, the positive technical indicators and strategic progress in the earnings call provide a more optimistic outlook. The valuation concerns due to the negative P/E ratio and lack of dividend yield slightly dampen the score.
William Blair
―
Buy
―
Reiterated
07/28/25
H.C. Wainwright
$26
Buy
114.34%
Upside
Reiterated
07/28/25
Zevra Therapeutics: Buy Rating Affirmed on European Market Expansion and Growth PotentialValuation and Risks. We base our valuation on our discounted cash flow valuation model. We use a weighted average cost of capital (WACC) of 10.8%, and an exit multiple of 8.5x on our 2031 estimates. ZVRA currently trades at ~2.8x EV/2026 Sales, which is lower than we believe it deserves to trade. With continued revenue growth from 2026+, as well as cash generation, we expect ZVRA shares to reward investors through revenue growth, as well as For definitions and the distribution of analyst ratings, analyst certifications, and other disclosures, please refer to pages 3 - 4 of this report.Zevra Therapeutics, Inc.
Roth MKM
$21
Buy
73.12%
Upside
Reiterated
07/22/25
Canaccord Genuity
$25
Buy
106.10%
Upside
Reiterated
07/17/25
Cantor Fitzgerald
$25→$29
Buy
139.08%
Upside
Reiterated
07/09/25
Citizens JMP
$19
Buy
56.64%
Upside
Reiterated
05/27/25
Maxim Group
$25
Buy
106.10%
Upside
Reiterated
05/15/25
Guggenheim
$20→$22
Buy
81.37%
Upside
Reiterated
03/12/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$12
Hold
-1.07%
Downside
Reiterated
07/26/25
Zevra Therapeutics' overall stock score reflects significant financial challenges, primarily negative profitability and cash flow issues. However, the positive technical indicators and strategic progress in the earnings call provide a more optimistic outlook. The valuation concerns due to the negative P/E ratio and lack of dividend yield slightly dampen the score.
William Blair
―
Buy
―
Reiterated
07/28/25
H.C. Wainwright
$26
Buy
114.34%
Upside
Reiterated
07/28/25
Zevra Therapeutics: Buy Rating Affirmed on European Market Expansion and Growth PotentialValuation and Risks. We base our valuation on our discounted cash flow valuation model. We use a weighted average cost of capital (WACC) of 10.8%, and an exit multiple of 8.5x on our 2031 estimates. ZVRA currently trades at ~2.8x EV/2026 Sales, which is lower than we believe it deserves to trade. With continued revenue growth from 2026+, as well as cash generation, we expect ZVRA shares to reward investors through revenue growth, as well as For definitions and the distribution of analyst ratings, analyst certifications, and other disclosures, please refer to pages 3 - 4 of this report.Zevra Therapeutics, Inc.
Roth MKM
$21
Buy
73.12%
Upside
Reiterated
07/22/25
Canaccord Genuity
$25
Buy
106.10%
Upside
Reiterated
07/17/25
Cantor Fitzgerald
$25→$29
Buy
139.08%
Upside
Reiterated
07/09/25
Citizens JMP
$19
Buy
56.64%
Upside
Reiterated
05/27/25
Maxim Group
$25
Buy
106.10%
Upside
Reiterated
05/15/25
Guggenheim
$20→$22
Buy
81.37%
Upside
Reiterated
03/12/25
Best Analysts Covering Zevra Therapeutics
1 Month
xxx
Success Rate
7/14 ratings generated profit
Average Return
+6.56%
reiterated a xxx
rating 18 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +6.56% per trade.
3 Months
xxx
Success Rate
9/14 ratings generated profit
Average Return
+13.54%
reiterated a xxx
rating 18 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +13.54% per trade.
1 Year
Success Rate
13/13 ratings generated profit
Average Return
+48.98%
reiterated a buy rating 3 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +48.98% per trade.
2 Years
xxx
Success Rate
13/13 ratings generated profit
Average Return
+81.48%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +81.48% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ZVRA Analyst Recommendation Trends
Rating
Feb 25
Mar 25
Apr 25
May 25
Jul 25
Strong Buy
6
13
13
14
12
Buy
0
1
1
2
2
Hold
9
7
5
8
10
Sell
0
0
0
1
1
Strong Sell
0
0
0
0
0
total
15
21
19
25
25
Each month's total comprises the sum of three months' worth of ratings.
ZVRA Financial Forecast
ZVRA Stock Forecast FAQ
What is ZVRA’s average 12-month price target, according to analysts?
Based on analyst ratings, Zevra Therapeutics’s 12-month average price target is 24.17.
What is ZVRA’s upside potential, based on the analysts’ average price target?
Zevra Therapeutics has 99.26% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ZVRA a Buy, Sell or Hold?
Zevra Therapeutics has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.
What is Zevra Therapeutics’s price target?
The average price target for Zevra Therapeutics is 24.17. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $29.00 ,the lowest forecast is $19.00. The average price target represents 99.26% Increase from the current price of $12.13.
The highest analyst price target is $29.00 ,the lowest forecast is $19.00. The average price target represents 99.26% Increase from the current price of $12.13.
What do analysts say about Zevra Therapeutics?
Zevra Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
How can I buy shares of ZVRA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.